Ukko

Ukko is a biotech firm focused on creating safe immunotherapies for quickly addressing allergies and other immune-related disorders. The company utilizes a unique technology platform that combines computational protein design with mRNA/LNP delivery to alter allergenic proteins. This approach seeks to mitigate or eliminate the risks of severe allergic reactions while eliciting a protective immune response. The Company is focused on changing the approach to prevent allergic reactions at the molecular level, striving to offer a safer and more targeted alternative to conventional desensitization techniques. This will lessen the treatment burden while meeting the critical needs of those vulnerable to severe allergic reactions to peanuts, with possibilities for extending the solution to other major allergens like milk, tree nuts, and respiratory triggers.

Domain

ukko.us

Employees

11-50

Last Funding

$45.0M

Founded

2015

Frequently Asked Questions

What technologies does Ukko use?+

Ukko uses 14 technologies including Sentry, Wix, GSAP.

What industry is Ukko in?+

Ukko operates in the Biotechnology industry.

Where is Ukko based?+

Ukko is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026